In Q1 FY2026 (ended March 31, 2026), GRAIL reported revenue of $40.8 million, up 28.1% year-over-year. Net loss was $93.2 million, improving 12.3% from the prior year. Operating loss was $135.8 million, also improving 11.6%. Diluted EPS was -$2.29, a 26.1% improvement. Cash stood at $69.3 million, and equity was $2.5 billion.
•Revenue grew 28.1% YoY to $40.8 million.
•Net loss narrowed 12.3% YoY to $93.2 million.
•Operating loss improved 11.6% YoY to $135.8 million.
•Diluted EPS improved 26.1% to -$2.29.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
GRAIL, Inc., a commercial-stage healthcare company provides multi-cancer early detection testing and services in the United States and globally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer
Development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. Incorporated in 2015, the company is headquartered in Menlo Park, California.
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its flagship product is Galleri, a cancer screening test designed for asymptomatic individuals over 50 years of age. The company also offers diagnostic aid tests to accelerate resolution for patients with clinical suspicion of cancer. Additionally, GRAIL provides development services supporting clinical studies, pilot testing, research, and therapy development. Its precision oncology portfolio includes a research-use-only (RUO) targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring.
Where is GRAIL, Inc. (GRAL) listed and in what currency?
GRAIL, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GRAL. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company's stock is accessible to investors through US-based brokerage accounts and is subject to the regulatory framework of the Nasdaq exchange.
What sector and industry does GRAIL, Inc. (GRAL) operate in?
GRAIL, Inc. operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry focuses on developing diagnostic tests, research tools, and services that aid in disease detection, monitoring, and treatment decisions. As a diagnostics and research company, GRAIL's work centers on advancing early cancer detection through innovative blood-based testing technologies, contributing to the broader field of precision oncology and preventive healthcare.
Where is GRAIL, Inc. (GRAL) headquartered and what markets does it serve?
GRAIL, Inc. is headquartered in Menlo Park, California, United States. The company serves both the United States and global markets, offering its multi-cancer early detection testing and services internationally. Its products, including the Galleri test and precision oncology portfolio, are available to healthcare providers and patients in various countries, though specific geographic expansion details are not provided in the available data.
How does GRAIL, Inc. (GRAL) generate revenue?
GRAIL, Inc. generates revenue primarily through the sale of its multi-cancer early detection tests and related services. Its main commercial product is Galleri, a screening test for asymptomatic individuals over 50. The company also earns from diagnostic aid tests for patients with suspected cancer and from development services that support clinical studies, pilot testing, research, and therapy development. Additionally, GRAIL's precision oncology portfolio, including its RUO methylation-based platform, contributes to revenue through applications in disease monitoring and recurrence detection. The company was incorporated in 2015 and is headquartered in Menlo Park, California.